Unknown

Dataset Information

0

Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study.


ABSTRACT: INTRODUCTION:Opioid agonist treatment is effective for opioid dependence and newer extended-release buprenorphine (BUP-XR) injections represent a significant development. The Community Long-Acting Buprenorphine (CoLAB) study aims to evaluate client outcomes among people with opioid dependence receiving 48 weeks of BUP-XR treatment, and examines the implementation of BUP-XR in diverse community healthcare settings in Australia. METHODS AND ANALYSIS:The CoLAB study is a prospective single-arm, multicentre, open-label trial of monthly BUP-XR injections in people with opioid dependence. Participants are being recruited from a network of general practitioner and specialist drug treatment services located in the states of New South Wales, Victoria and South Australia in Australia. Following a minimum 7 days on 8-32?mg of sublingual buprenorphine (±naloxone), participants will receive monthly subcutaneous BUP-XR injections administered by a healthcare practitioner at intervals of 28 days (-2/+14 days). The primary endpoint is participant retention in treatment at 48 weeks after treatment initiation. Secondary endpoints will evaluate dosing schedule variations, craving, withdrawal, substance use, health and well-being, and client-reported treatment experience. Qualitative and costing substudies will examine implementation barriers and facilitators at the client and provider level. ETHICS AND DISSEMINATION:The study has received ethics approval from the St Vincent's Hospital Sydney Human Research Ethics Committee (Ref. HREC/18/SVH/221). The findings will be disseminated via publication in peer-reviewed journals, presentations at national and international scientific conferences, and in relevant community organisation publications and forums. TRIAL REGISTRATION NUMBER:NCT03809143 PROTOCOL IDENTIFIER: CoLAB1801, V.4.0 dated 01 August 2019.

SUBMITTER: Larance B 

PROVIDER: S-EPMC7398105 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study.

Larance Briony B   Byrne Marianne M   Lintzeris Nicholas N   Nielsen Suzanne S   Grebely Jason J   Degenhardt Louisa L   Shahbazi Jeyran J   Shanahan Marian M   Lancaster Kari K   Dore Gregory G   Ali Robert R   Farrell Michael M  

BMJ open 20200731 7


<h4>Introduction</h4>Opioid agonist treatment is effective for opioid dependence and newer extended-release buprenorphine (BUP-XR) injections represent a significant development. The Community Long-Acting Buprenorphine (CoLAB) study aims to evaluate client outcomes among people with opioid dependence receiving 48 weeks of BUP-XR treatment, and examines the implementation of BUP-XR in diverse community healthcare settings in Australia.<h4>Methods and analysis</h4>The CoLAB study is a prospective  ...[more]

Similar Datasets

| S-EPMC8111483 | biostudies-literature
| S-EPMC7188268 | biostudies-literature
| S-EPMC6145749 | biostudies-literature
| S-EPMC6766787 | biostudies-literature
| S-EPMC5913635 | biostudies-other
| S-EPMC5806119 | biostudies-literature
| S-EPMC6771955 | biostudies-literature
| S-EPMC8016750 | biostudies-literature
| S-EPMC5584886 | biostudies-literature
| S-EPMC5354129 | biostudies-literature